Biotech Values

[mcbio]

Was that expected? It's also only two patients so it would not be prudent to draw conclusions about which types of patients are more likely to respond.

Just pointing out that the responses came from 2 out of 7 patients in that specific subgroup. Obviously too small and too early to know for sure if that will be a trend going forward. But I'm sure ARRY/NVS will explore that going forward.